التفاصيل البيبلوغرافية
| العنوان: |
TRK Inhibitors in Non-Small Cell Lung Cancer. |
| المؤلفون: |
Harada, Guilherme, Gongora, Aline Bobato Lara, da Costa, Cesar Martins, Santini, Fernando Costa |
| المصدر: |
Current Treatment Options in Oncology; May2020, Vol. 21 Issue 5, p1-12, 12p |
| مستخلص: |
Opinion Statement: Care should be taken to ensure that the diagnostic strategy for a recently diagnosed advanced non-small cell lung cancer includes NTRK fusion testing. RNA sequencing is the gold standard method of detection of NTRK fusion; however, pan-TRK immunohistochemistry could be used as a screening method with good sensitivity. Larotrectinib and entrectinib are approved therapies for TRK fusion-positive lung cancers as first or subsequent lines of therapy. TRK inhibition has demonstrated clinically meaningful, deep, and durable systemic and central nervous system responses. Larotrectinib and entrectinib have a manageable safety profile, including some TRK-related adverse events, such as dizziness and weight gain. At disease progression on first-generation TRK inhibitors, enrollment on a clinical trial should be encouraged, as new-generation TRK inhibitors are being tested. [ABSTRACT FROM AUTHOR] |
|
Copyright of Current Treatment Options in Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
